CLDI PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

CLDI ▲ +3.95% at T+5d

NEUTRAL call ✓ call won +3.95% · α vs SPY +2.87% · entry $0.1770 → $0.1840

Next anchor: T+20d in 14d

Currently $0.1750 · -1.13% from $0.1770 entry

Entry anchored
May 22, 03:59 PM ET
via Databento tick

T+1d

+7.91%

call +7.91% · α +7.90%

$0.1910

settled 14d ago

T+5d

+3.95%

call +3.95% · α +2.87%

$0.1840

settled 8d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Calidi Biotherapeutics announced that two abstracts on its RedTail platform (CLD-401 and CLD-501) were accepted for publication at the 2026 ASCO Annual Meeting. The preclinical data highlights systemic virotherapy targeting tumors and delivering IL-15 superagonist or T-cell engager payloads. The news is pre-clinical and lacks quantitative drug results, providing a low-impact catalyst ahead of the meeting.

Actionable Insight

Monitor ASCO presentations (May 29 – June 2) for any positive preclinical data that could serve as a near-term catalyst. Absent data, the stock likely remains range-bound with low liquidity. Given historical poor T+20 performance (25% win rate), avoid overreacting to abstract acceptance alone.

Key Facts

Two abstracts accepted for ASCO 2026 (May 29 – June 2, 2026) on CLD-401 and CLD-501.
CLD-401 is a systemically delivered virotherapy expressing IL-15 superagonist.
CLD-501 is a systemically delivered virotherapy expressing a TROP-2 T-cell engager and IL-15 SA.
Company expects to file an IND for CLD-401 by end of 2026.
Preclinical data only; no financial or clinical milestone achieved.

Financial Impact

No financial data disclosed; pre-revenue company with $3M market cap.

Risk Factors

Preclinical data may not translate to clinical success; high risk of failure.
Company needs additional capital to fund IND and trials; dilution risk.
Low market cap and OTC listing increase volatility and liquidity risk.

Market Snapshot

Exchange

OTC

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3301010

6 reports for CLDI

T+1T+5T+20T+60

33% Hit rate 1 of 3 directional calls best @ T+60▲ +53.89%Mar 10, 2026

Filters

Reports for CLDI — sortable, filterable
	Type				Now
May 26, 2026 14d ago	Press Release NEUTRAL ★ 4/10	$0.1770 $0.1840	▲ +3.95%	▲ +2.87%	$0.1750 (−1.13%)
May 22, 2026 18d ago	Press Release BEARISH ★ 7/10	$0.1770 $0.1800	▼ −1.69%	▼ −0.48%	$0.1750 (+1.13%)
Apr 20, 2026 7w ago	Press Release BULLISH ★ 7/10	$0.2500 $0.2380	▼ −4.80%	▼ −5.71%	$0.1750 (−30.00%)
Mar 27, 2026 10w ago	Press Release MIXED ★ 5/10	$0.2390 $0.2420	▲ +1.26%	▼ −3.04%	$0.1750 (−26.78%)
Mar 10, 2026 13w ago	Press Release BEARISH ★ 7/10	$0.3600 $0.3140	▲ +12.78%	▲ +11.87%	$0.1750 (+51.39%)
Mar 5, 2026 13w ago	Press Release NEUTRAL ★ 4/10	$0.3610 $0.3180	▼ −11.91%	▼ −10.38%	$0.1750 (−51.52%)

US Market Status

Market Closed — Opens Thu (9h 49m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access